Steadybase.

NewAmsterdam Pharma Co N.V.

Website LinkedIn Latest 10-K
  • NAMS · Nasdaq
  • Pharmaceutical Preparations
  • Narrden, P7
  • 100 employees
  • CIK 0001936258

Updated from SEC filings through

Top things to know

Executives

NewAmsterdam Pharma Co N.V. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Narrden, P7. It trades as NAMS on Nasdaq. Revenue was $22.5M in the fiscal year ending December 31, 2025, -50.6% from the year before. It reported about 100 employees. Michael H. Davidson is Chief Executive Officer.

Five-year financials

MetricFY2025FY2024FY2023FY2022FY2021
Revenue $22.5M
10-K, 2026-02-18
$45.6M
10-K, 2026-02-18
$14.1M
10-K, 2026-02-18
$103M
10-K, 2025-02-26
Not on file
Operating income -$226M
10-K, 2026-02-18
-$176M
10-K, 2026-02-18
-$183M
10-K, 2026-02-18
-$3.6M
10-K, 2025-02-26
-$35.0M
10-K, 2024-02-28
SG&A $106M
10-K, 2026-02-18
$70.4M
10-K, 2026-02-18
$37.6M
10-K, 2026-02-18
$19.5M
10-K, 2025-02-26
$6.0M
10-K, 2024-02-28
Net income -$204M
10-K, 2026-02-18
-$242M
10-K, 2026-02-18
-$177M
10-K, 2026-02-18
-$22.6M
10-K, 2025-02-26
-$41.8M
10-K, 2024-02-28

Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.

Leadership and board

NameTitleSource
Michael H. Davidson Michael H. Davidson Chief Executive Officer Form 4, September 15, 2026
Ian Somaiya Ian Somaiya Chief Financial Officer 10-K, February 18, 2026
Mayur Ian Somaiya Chief Financial Officer Form 4, January 22, 2026
Robert William Gunning Vice President, Controller Form 4, September 3, 2026
Johannes Jacob Pieter Kastelein Chief Scientific Officer Form 4, August 25, 2026
Louise Frederika Kooij Chief Accounting Officer Form 4, July 22, 2026
John Kastelein, M.D. John Kastelein, M.D. Chief Scientific Officer, Non-Executive Director 10-K, February 18, 2026
Mark C. McKenna Vice Chair, Non-Executive Director 10-K, February 18, 2026
William H. Lewis, J.D., M.B.A. Chair, Non-Executive Director 10-K, February 18, 2026
Adele Gulfo Non-Executive Director 10-K, February 18, 2026
James N. Topper, M.D., Ph.D. Non-Executive Director 10-K, February 18, 2026
Janneke van der Kamp Non-Executive Director 10-K, February 18, 2026
John W. Smither Non-Executive Director 10-K, February 18, 2026
Louis Lange, M.D., Ph.D. Non-Executive Director 10-K, February 18, 2026
Wouter Joustra Non-Executive Director 10-K, February 18, 2026

What NewAmsterdam Pharma Co N.V. does

We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy.

Item 1. Business, 10-K for the year ending December 31, 2025

Shares and governance

Shares outstanding 119.9 million (as of November 2, 2026) 10-Q, November 4, 2026
Public float $1.3B (as of June 30, 2025) 10-K, February 18, 2026
Reportable segments 1 (period ending September 30, 2026) 10-Q, November 4, 2026
Latest proxy statement Meeting May 6, 2026 (filed May 6, 2026) DEF 14A, May 6, 2026
Auditor Deloitte Accountants B.V (Eindhoven, The Netherlands) Latest 10-K

Insider trades

Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.

DateInsiderTradeSharesValueSource
September 30, 2026 Johannes Jacob Pieter Kastelein
Chief Scientific Officer
Sale 50,246 $1.3M Form 4, October 2, 2026
September 14, 2026 Michael H. Davidson
Chief Executive Officer
Buy 10,000 $227K Form 4, September 15, 2026
September 4, 2026 John W. Smither
Director
Sale 1,600 $41K Form 4, September 9, 2026
August 24, 2026 Johannes Jacob Pieter Kastelein
Chief Scientific Officer
Sale 125,000 $3.4M Form 4, August 25, 2026
July 20, 2026 Louise Frederika Kooij
Chief Accounting Officer
Sale 105,000 $3.2M Form 4, July 22, 2026
June 22, 2026 Louise Frederika Kooij
Chief Accounting Officer
Sale 40,000 $1.2M Form 4, June 24, 2026
May 26, 2026 Louise Frederika Kooij
Chief Accounting Officer
Sale 65,000 $2.3M Form 4, May 27, 2026
March 11, 2026 Louis G. Lange
Director
Sale 44,619 $1.4M Form 4, March 12, 2026

Recent 8-K events

Frequently asked questions about NewAmsterdam Pharma Co N.V.

What does NewAmsterdam Pharma Co N.V. do?
In its own words, from Item 1 of its 10-K: "We are a late-stage biopharmaceutical company whose mission is to improve patient care in populations with cardiometabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well tolerated and convenient low-density lipoprotein cholesterol (“LDL-C”) lowering therapy."
What is NewAmsterdam Pharma Co N.V.'s revenue?
$22.5M for the fiscal year ending December 31, 2025, from its 10-K filed February 18, 2026.
Is NewAmsterdam Pharma Co N.V. profitable?
NewAmsterdam Pharma Co N.V. reported net income of -$204M for the fiscal year ending December 31, 2025.
How many employees does NewAmsterdam Pharma Co N.V. have?
About 100 as of December 31, 2025, as stated in its annual report.
Who is the CEO of NewAmsterdam Pharma Co N.V.?
Michael H. Davidson, Chief Executive Officer, as named in a 4 filed September 15, 2026.
Who is the CFO of NewAmsterdam Pharma Co N.V.?
Ian Somaiya, Chief Financial Officer, as named in a 10-K filed February 18, 2026.
Where is NewAmsterdam Pharma Co N.V. headquartered?
Narrden, P7.
What is NewAmsterdam Pharma Co N.V.'s stock ticker?
NAMS, NAMSW on Nasdaq.
What industry is NewAmsterdam Pharma Co N.V. in?
Pharmaceutical Preparations, SIC code 2834.
What is NewAmsterdam Pharma Co N.V.'s website?
newamsterdampharma.com.
When does NewAmsterdam Pharma Co N.V. report earnings next?
January 8, 2027. This is an estimate from past filing dates, not a confirmed date.
Is NewAmsterdam Pharma Co N.V. a public company?
Yes. NewAmsterdam Pharma Co N.V. files with the SEC under CIK 0001936258 and trades as NAMS.
Who audits NewAmsterdam Pharma Co N.V.?
Deloitte Accountants B.V, Eindhoven, The Netherlands, as named in its latest annual report (10-K).
How many shares of NewAmsterdam Pharma Co N.V. are outstanding?
119.9 million shares as of November 2, 2026, from its 10-Q filed November 4, 2026.
What is NewAmsterdam Pharma Co N.V.'s public float?
$1.3B as of June 30, 2025, as reported on the cover of its 10-K filed February 18, 2026.
How many business segments does NewAmsterdam Pharma Co N.V. report?
1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
When is NewAmsterdam Pharma Co N.V.'s annual shareholder meeting?
May 6, 2026, per its proxy statement (DEF 14A) filed May 6, 2026.
Have NewAmsterdam Pharma Co N.V. insiders traded stock recently?
Since July 16, 2025, officers and directors reported 25 open-market sales worth about $72.4M and 4 purchases worth about $285K on Forms 4 and 5. The most recent: Johannes Jacob Pieter Kastelein (Chief Scientific Officer) sold 50,246 shares on September 30, 2026.